Vorinostat Completed Phase 2 Trials for Non Small Cell Lung Carcinoma (NSCLC) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00798720Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer